Yue Wu, PhD, earned his doctoral degree in Microbiology from Beijing Agricultural University, China, in 1998. Dr. Wu joined the staff of Roswell Park Cancer Institute in 2003 as a postdoctoral research affiliate in the Department of Cancer Prevention and Control, within the division of Cancer Prevention and Population Sciences. He was appointed to Affiliate Member in 2007, and HRI Scientist, Assistant Professor of Oncology in 2008.
Dr. Wu’s research interest is in androgen metabolism and androgen receptor signaling in prostate cancer. Specifically, his research projects are focused on prostatic androgen trafficking and metabolism by prostatic epithelial cells and cancer cells, and how androgen metabolism affects biology and clinical characteristics of prostate cancer. The ultimate goal is to delineate mechanisms underlying the progression of prostate cancer to castration recurrent disease, and to identify novel modalities to prevent or treat castration recurrent prostate cancer.
Current active research initiatives include:
1) Identification of cell membrane-located transporters that are critical for prostate cancer cells to obtain androgens from the circulation, and the potential of targeting these transporters to achieve complete androgen deprivation;
2) To examine the role of genetic variations of androgen transporters in racial disparity in prostate cancer aggressiveness;
3) To evaluate the importance of adrenal androgen uptake and metabolism to castration-recurrent prostate cancer, and to identify approaches to specifically deprive cancer cells of adrenal androgens;
4) To understand the role of prostatic endothelium in regulation of blood – prostate transit of androgens, and to develop prostate-specific approaches for organ-specific androgen deprivation.
Ou L, Wu Y, Ip C, Ip MM. Apoptosis induced by trans-10,cis-12 conjugated linoleic acid in mammary tumor cells is mediated through endoplasmic reticulum stress. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:805
Wu Y, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: Increasing the efficacy of taxane against prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:312
Chhipa RR, Lee K-S, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Molecular cancer research : MCR 2009; 7(9):1543-1552
Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer.Cancer biology and therapy 2009; 8(2):146-152
Cheng J, Wu Y, Mohler JL, Ip C. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer biology and therapy 2010; 9(12):1033-1042
Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular signalling 2010; 22(10):1554-1561
Wu Y , Chhipa RR , Cheng J , Zhang H , Mohler JL , Ip C. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer research 2010; 30(10):3895-3901
Chhipa RR, Wu Y, Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cellular signalling 2011; 23(9):1466-1472
Wu Y, Chhipa RR, Zhang H, Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer biology and therapy 2011;11(10):902-909
Wu Y, Godoy A, Azzouni F, Wilton JH, Ip C, Mohler JL. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013 Sep;73(13):1470-82.
Chhipa RR, Halim D, Cheng J, Zhang HY, Mohler JL, Ip C, Wu Y. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate. 2013 Oct;73(14):1483-94.